2025年司帕生坦正版的价格是多少？

Sparsentan is a drug used to treat primary immunoglobulin A nephropathy (IgAN). It was developed by the American company Travere Therapeutic and was approved by the US FDA in 2023. This article will introduce in detail the price of genuine Sparsentan in 2025, medication preparation, and medication for special groups to help patients and medical practitioners better understand this drug.

What is the price of genuine sparsentan in 2025?

As a new type of drug, its price varies depending on the manufacturer and region. In 2025, the price of genuine sparsentan will still be one of the focuses of attention for patients.

The price of sparsentan produced by Travere Therapeutic in the United States

The specification of sparsentan produced by Travere Therapeutic in the United States is 400mg*30 tablets/box, and the reference price in 2025 is approximately US$15,277 per box. This price reflects the high R&D costs and technical advantages of the original drug, but it also places higher demands on patients’ financial burden.

The price of generic drugs produced by Lucius in Laos

The specification of generic Sparsentan produced by Lucius in Laos is also 400mg*30 tablets/box, and the reference price in 2025 is about US$808 per box. The price of generic drugs is significantly lower than that of original drugs, providing patients with a more economical choice, but they need to pay attention to the quality and reliability of the source when purchasing.

Reasons for price differences

The price difference between original drugs and generic drugs is mainly due to factors such as R&D investment, patent protection and market exclusivity period. Original drugs are more expensive in the early stages of their launch, while generic drugs enter the market after patent expiration and are more competitively priced. Patients need to weigh the pros and cons based on their own financial situation and doctor's advice when making a choice.

Preparation for the administration of Sparsentan

The administration of Sparsentan requires strict preparation and monitoring. The following describes the three aspects of pre-medication inspection, dosage adjustment and precautions.

Pre-medication tests

Before starting treatment with sparsentan, patients need to complete a number of tests, including liver function, kidney function, pregnancy test (for female patients) and blood pressure monitoring. These tests help assess a patient's suitability for medication and provide baseline data for subsequent treatment.

Dose adjustment

The initial dose of sparsentan is 200 mg once a day. After 14 days, if the patient tolerates it well, it can be increased to 400 mg once a day. If adverse reactions such as elevated transaminases or hypotension occur during treatment, the dose must be adjusted or the medication must be suspended according to the doctor's recommendations.

Precautions

Liver function, blood pressure and blood potassium levels need to be monitored regularly during medication. Avoid combination with strong CYP3A inhibitors or inducers, and be aware of possible embryo-fetal toxicity caused by the drug. Patients must strictly follow the doctor's instructions and are not allowed to adjust the dosage or stop medication without authorization.

Special population use of sparsentan

The use of sparsentan in different groups of people requires special attention. The following is explained from three aspects: pregnant women, lactating women and patients with liver damage.

Contraindicated in pregnant women

Sparsentan is embryo-fetal toxic and may cause birth defects or fetal death, so it is contraindicated in pregnant women. Female patients of reproductive potential need to confirm a negative pregnancy test before taking the drug, and take effective contraceptive measures during treatment and within one month after stopping the drug.

Use with caution in lactating women

There is currently insufficient data to prove whether sparsentan will be excreted through breast milk. However, for safety reasons, it is recommended that lactating women suspend breastfeeding while taking the drug to avoid potential risks to the baby.

Avoid use in patients with liver impairment

Sparsentan may cause severe hepatotoxicity, so patients with hepatic impairment (Child-Pugh Class A-C) should avoid use. During the period of medication, transaminase and bilirubin levels need to be monitored regularly, and any abnormalities should be dealt with promptly.

Special groups need to be extra cautious when using medication. Doctors should weigh the pros and cons according to the patient's specific situation and formulate a personalized treatment plan.